pharmaphorum| News & views on pharma and biotech’s evolving future

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

The conflict in the Middle East is exposing dangerous prepar...

If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

Digital

AI in clinical trials for protocol ingestion

From static documents to strategic capability: The case for ...

Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.

R&D

LSX2026: Endogenous tissue restoration in vascular disease –...

Featured Content

R&D

The conflict in the Middle East is exposing dangerous prepar...

If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

Sales & Marketing

Sponsored

Pushing through barriers to commercial launch success, with ...

In this sponsored pharmaphorum podcast, Amanjeet Singh Saluja, a Principal at Axtria, discusses the current state of affairs in launch success.

R&D

LSX2026: Endogenous tissue restoration in vascular disease –...

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Newsletters and Deep Dive
digital magazine

Latest News

News

Obesity biotech Kailera's record-breaking IPO

When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled.

News

OpenAI introduces GPT-Rosalind, its drug discovery AI

In this week's second AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, named after UK scientist Rosalind Franklin.

News

Multiple myeloma drug Blenrep backed for wider NHS use

The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.

News

Trump names Erica Schwartz to fill leadership void at CDC

Former Deputy Surgeon General Erica Schwartz could end months at the CDC without Senate-confirmed leadership if she becomes Director.

Views & Analysis

R&D

The conflict in the Middle East is exposing dangerous prepar...

If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.

Digital

From static documents to strategic capability: The case for ...

Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.

R&D

LSX2026: Endogenous tissue restoration in vascular disease –...

R&D

Neuroplasticity modulators as innovative potential disease-m...

In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Redesigning obesity trials for a chronic disease era

R&D

GLP-1s: Five years that changed metabolic medicine

R&D

The trust gap: GLP-1s and the new information economy of obe...

White Papers & Webinar

R&D

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Sales & Marketing

Sponsored

What HCPs Say Pharma Gets Wrong About Survey Research

Most market researchers already know the standard rules: keep surveys concise, write clear questions, and reduce unnecessary respondent burden.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Podcasts & Video

R&D

Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content